Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: 1. Age ≥18 years; 2. Histologically or cytologically confirmed SCLC; 3. Advanced SCLC who failed first-line platinum-based chemotherapy with or without checkpoint inhibitors; 4. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1; 5. Life expectancy of ≥3 months; 6. At least one measurable lesion is present according to the efficacy evaluation criteria for RECIST 1.1（Lesions that have received radiotherapy within 6 months prior to the first dose cannot be used as target lesions） 7. No untreated central nervous system (CNS) metastases or CNS were stable for ≥1 month after treatment 8. Have adequate organ function; 9. All female must have had a negative serum pregnancy test within 72 hours of the first dosing and not be lactating, and study participants and their partners must use effective contraception during the trial and for 6 months after the last dosing of the trial drug. 10. Able and willing to provide a written informed consent; Exclusion…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source